Antibody-target Binding in Living Tumors Using Macroscopy Fluorescence Lifetime Imaging
Multiphoton Microscopy in the Biomedical Sciences XXII(2022)
Abstract
There is a continuing need to develop preclinical molecular imaging modalities to guide the development and optimization of targeted therapies in oncology. We have established Macroscopic Fluorescence Lifetime Imaging (MFLI) associated with Forster Resonance Energy Transfer (FRET) to report quantitatively on antibody-target engagement in live intact animals at the organ level. Here, we use FLI FRET imaging to quantify the binding of near infrared labeled antibody drugs to breast cancer cells or tumor xenografts. In combination with antibody engineering, this approach provides a robust analytical tool to optimize the binding and uptake of antibody-target binding during tumor progression and treatment.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined